JHU ICTR

Do you want to participate in a clinical trial at Johns Hopkins?
For those who are interested in participating in a COVID-19 Clinical Trial, please send an email to Covid19Research@jhmi.edu
If you are interested in joining a clinical trial, you can type a keyword in the search box below to find a research study.


RankSearch Results
1. andquot;Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancerandquot;
Prostate; Hormone Antagonists; Ablation Techniques; Radiation (Recruiting)
 
2. Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer; Renal Carcinoma; Kidney Cancer Metastatic (Recruiting) Last updated: March 1, 2023
 
3. Combined Aerobic and Resistance Exercise Training in Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma Metastatic (Recruiting) Last updated: March 28, 2022
 
4. The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry
Kidney Neoplasm (Recruiting) Last updated: October 14, 2021
 
5. Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma (Recruiting) Last updated: November 29, 2022
 
6. Study of Kidney Tumors in Younger Patients
Adult Cystic Nephroma; Anaplastic Kidney Wilms Tumor; Angiolipoma; Cellular Congenital Mesoblastic Nephroma; Classic Congenital Mesoblastic Nephroma; Clear Cell Sarcoma of the Kidney; Congenital Mesoblastic Nephroma; Cystic Partially Differentiated Kidney Nephroblastoma; Diffuse Hyperplastic Perilobar Nephroblastomatosis; Extrarenal Rhabdoid Tumor; Kidney Medullary Carcinoma; Kidney Neoplasm; Kidney Oncocytoma; Kidney Wilms Tumor; Metanephric Adenofibroma; Metanephric Adenoma; Metanephric Stromal Tumor; Metanephric Tumor; Mixed Congenital Mesoblastic Nephroma; Ossifying Renal Tumor of Infancy; Papillary Renal Cell Carcinoma; Renal Cell Carcinoma; Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions; Rhabdoid Tumor of the Kidney; Wilms Tumor (Recruiting) Last updated: September 2, 2022
 
7. Renal Retention in High Grade Upper Tract Urothelial Cancer
High Grade Urothelial Carcinoma; Bladder Cancer; Urothelial Carcinoma Bladder (Not yet recruiting) Last updated: January 5, 2023
 
8. Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Renal Cell Carcinoma (Recruiting) Last updated: March 17, 2023
 
9. Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma (Recruiting) Last updated: October 13, 2022
 
10. A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Clear Cell Renal Cell Carcinoma (Recruiting) Last updated: March 29, 2023
 
11. A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Advanced Solid Tumor; Castration-Resistant Prostatic Cancer; Malignant Melanoma; Pancreatic Ductal Carcinoma; Hepatocellular Cancer; Epithelial Ovarian Cancer; Renal Cell Carcinoma (Recruiting) Last updated: March 8, 2023
 
12. Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Refractory and/or Relapsed Metastatic Solid Tumors (Recruiting) Last updated: August 12, 2022
 
13. Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Hematologic Malignancies (Recruiting) Last updated: February 22, 2023
 
14. Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Malignant Solid Neoplasm; Recurrent Adrenal Gland Pheochromocytoma; Recurrent Ectomesenchymoma; Recurrent Ependymoma; Recurrent Ewing Sarcoma; Recurrent Hepatoblastoma; Recurrent Kidney Wilms Tumor; Recurrent Langerhans Cell Histiocytosis; Recurrent Malignant Germ Cell Tumor; Recurrent Malignant Glioma; Recurrent Medulloblastoma; Recurrent Melanoma; Recurrent Neuroblastoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Osteosarcoma; Recurrent Peripheral Primitive Neuroectodermal Tumor; Recurrent Rhabdoid Tumor; Recurrent Rhabdoid Tumor of the Kidney; Recurrent Rhabdomyosarcoma; Recurrent Soft Tissue Sarcoma; Recurrent Thyroid Gland Carcinoma; Recurrent WHO Grade 2 Glioma; Refractory Adrenal Gland Pheochromocytoma; Refractory Ependymoma; Refractory Ewing Sarcoma; Refractory Hepatoblastoma; Refractory Langerhans Cell Histiocytosis; Refractory Malignant Germ Cell Tumor; Refractory Malignant Glioma; Refractory Medulloblastoma; Refractory Melanoma; Refractory Neuroblastoma; Refractory Non-Hodgkin Lymphoma; Refractory Osteosarcoma; Refractory Peripheral Primitive Neuroectodermal Tumor; Refractory Rhabdoid Tumor; Refractory Rhabdoid Tumor of the Kidney; Refractory Rhabdomyosarcoma; Refractory Soft Tissue Sarcoma; Refractory Thyroid Gland Carcinoma; Refractory WHO Grade 2 Glioma (Recruiting) Last updated: March 9, 2023
 
15. TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Cancer (Recruiting) Last updated: February 3, 2023
 
16. A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Anaplastic Kidney Wilms Tumor; Recurrent Kidney Wilms Tumor; Stage II Kidney Wilms Tumor; Stage III Kidney Wilms Tumor; Stage IV Kidney Wilms Tumor (Recruiting) Last updated: March 8, 2023
 
17. NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Radiotherapy; Immunotherapy; Microsatellite Instability-High Solid Malignant Tumour; Metastasis From Malignant Tumor of Liver; Squamous Cell Carcinoma of Head and Neck; Metastasis From Malignant Tumor of Cervix; Metastatic Renal Cell Carcinoma; Metastasis From Malignant Melanoma of Skin (Disorder); Metastatic Triple-Negative Breast Carcinoma; Metastatic NSCLC; Metastasis From Malignant Tumor of Bladder (Disorder) (Recruiting) Last updated: January 26, 2023
 
18. Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Solid Tumor (Recruiting) Last updated: December 1, 2022
 
19. Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma (Recruiting) Last updated: March 28, 2023